Compare ELWT & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELWT | RFL |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | Telecommunications Equipment | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.5M | 69.7M |
| IPO Year | N/A | 2017 |
| Metric | ELWT | RFL |
|---|---|---|
| Price | $7.39 | $1.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 28.7K | ★ 65.0K |
| Earning Date | 05-15-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $28.81 | N/A |
| Revenue Next Year | $70.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $4.11 | $1.12 |
| 52 Week High | $9.72 | $3.19 |
| Indicator | ELWT | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 63.86 |
| Support Level | $6.01 | $1.28 |
| Resistance Level | $7.57 | $1.44 |
| Average True Range (ATR) | 1.06 | 0.07 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 10.19 | 100.00 |
Elauwit Connection Inc is a provider of broadband Internet networks for the multifamily and student housing property sector. It designs, installs, operates, and maintains new fiber-optic and WiFi networks throughout each contracted property. Once installed, property owners begin selling Internet connectivity over Elauwit's network directly to their residents at monthly prices and terms of their choosing. Elauwit, in turn, provides all resident activation, onboarding, customer support, and network monitoring and maintenance services in exchange for a fixed monthly fee based on the number of units in the property times a monthly per-unit wholesale price. Its contracts with property owners generally have five to eight-year terms. Geographically, the company mainly operates in the U.S.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.